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G. H. MURATA, C. 0. KAPSNER, D. J. LIUM, AND H. K. BUSBY 
General Internal Medicine and Pulmonary Sections, Veterans Affairs Medical Center, and the 
Department of Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico, 
U.S.A. 
The aim of this study was to look at changes in peak expiratory flow rates (PEFR) prior to emergency department 
visits for decompensated chronic obstructive pulmonary disease (COPD). It was designed as a prospective, 
double-blind study at the Albuquerque Veterans Affairs Medical Center. Twelve patients with an irreversible 
component of airflow obstruction on pulmonary function tests were assessed. At entry, all subjects were instructed 
in the use of a mini-Wright peak flow meter with electronic data storage. They then entered a 6-month monitoring 
phase in which they recorded PEFR twice daily, before and after bronchodilators. The meter displays were disabled 
so that the patients and their physicians were blinded to all values. Medical care was provided in the customary 
manner. Patients were considered to have respiratory decompensation if they required treatment for airflow 
obstruction in the Emergency Department (ED) and no other causes of dyspnea could be identified. Simple linear 
regression was used to model changes in PEFR over time. The 12 subjects had 22 episodes of respiratory 
decompensation during 1741 patient-days of observation. Two episodes could not be analysed because of missing 
values. Ten episodes in seven subjects were characterized by a significant linear decline in at least one peak flow 
parameter prior to presentation. The mean rates of change for the four daily parameters varied from 0.22% to 0.27% 
predicted per day (or 1.19 to 1.44 1 min - ’ day- ‘). The average decrement in these parameters ranged from 30.0 to 
33.8 lmin-’ (or 18.65259% of their baseline values). No temporal trends were found for the 10 episodes occurring 
in the other five subjects. 
We concluded that respiratory decompensation is characterized by a gradual decline in PEFR in about half of 
cases. Future studies should be done to elucidate the mechanisms of respiratory distress in the other cases. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is a debili- 
tating illness characterized by slowly progressive air flow 
obstruction (1,2). In some patients, the indolent course is 
interrupted by episodes in which lung function deteriorates 
rapidly, sometimes to life-threatening levels (3). The degree 
of obstruction at presentation is usually expressed in 
terms of the l-s forced expiratory volume (FEV,) (46). In 
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emergency departments, FEV, correlates with arterial 
PaCO, (S), the risk of relapse (4), and the need for 
hospitalization (6). However, there is surprisingly little 
information about the amount of airway function lost, or 
the rate at which this loss occurs. This data is difficult to 
obtain because: (a) the onset can be insidious; (b) symptoms 
and physical findings do not accurately reflect the degree of 
obstruction (7-l 1); (c) it is often difficult to establish a 
‘baseline’ value; and (d) it is impractical to monitor subjects 
wit;1 conventional spirometry. 
Peak flow monitoring is a safe, simple, and inexpensive 
method for monitoring airflow obstruction in the out- 
patient setting. We performed a prospective, double-blind 
study of peak flow monitoring in patients with advanced 
COPD. The purpose of this paper is to describe changes in 
peak expiratory flow rates (PEFR) prior to emergency 
department visits for respiratory decompensation in 12 
subjects. 
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Methods 
SUBJECTS 
The Albuquerque VA Medical Center is a 400-bed, acute- 
care facility serving veterans in New Mexico and west 
Texas. Names of potential subjects were gathered from the 
logs of the Emergency Department (ED) and Urgent Care 
Clinic, pharmacy printouts of prescriptions for albuterol, 
records of patients on home oxygen, and appointments to 
Chest Clinic. Patients were included in this study if they met 
standard criteria for the diagnosis of COPD (12) and had 
an irreversible component of airflow obstruction on initial 
pulmonary function tests. Airflow obstruction was consid- 
ered to have an irreversible component if the FEV, was less 
than 75% predicted and the ratio of FEV, to vital capacity 
(VC) was less than 75%, before and after bronchodilators. 
Patients were excluded from the study if they had more 
than 15% improvement in FEV, with bronchodilators. 
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Patients were also excluded if: 
the onset of symptoms was before the age of 40; 
they had nasal polyposis, aspirin sensitivity, or multiple 
allergies; 
they did not have the capacity or motivation to measure 
PEFR at home; 
they had other medical problems for which dyspnea was 
a common complaint; 
they were unlikely to survive the follow-up period of 
6 months; 
they were immunosuppressed or taking immunosuppres- 
sive drugs other than corticosteroids or 
they had alternative sources of medical care. 
EQUIPMENT 
Peak flow rates were measured on a hand-held, mini-Wright 
device with electronic data storage (VMX Mini-Log@, 
Clement Clark, Columbus, OH, U.S.A.). The best of three 
expiratory maneuvers was recorded. The displays were 
disabled so that the patients, their physicians, and the 
investigators were blinded to all values. 
STUDY PROTOCOL 
Prospective subjects were followed until: 
1. there were no episodes of respiratory distress requiring 
an ED visit or hospitalization; 
2. there was no adjustment of maintenance medications or 
institution of new bronchodilator treatment and 
3. there were no intercurrent illnesses requiring antibiotic 
therapy for two weeks. 
At the conclusion of this run-in period, they were given a 
history and physical examination and underwent formal 
pulmonary function testing. Spirometry was performed on 
a Jaeger Pneumoscope@ (Wuerzburg, Germany). Equip- 
ment and procedures in our laboratory conform to stan- 
dards set by the American Thoracic Society (13). All 
subjects were trained in the use of the peak flow meter. 
Instruction continued until the patient could generate 
reproducible measurements under the supervision of a 
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research technician. For the next 6 months, patients 
recorded PEFR at 8.00 a.m. and 4.00 p.m. daily, before and 
after bronchodilators. The bronchodilator was albuterol or 
metaproterenol administered by metered dose inhaler with 
a spacer. Postbronchodilator PEFR was measured 20 min 
after the second of two doses but before the administration 
of other inhaled medications. The four daily measurements 
are hereafter referred to as AMPRE, AMPOST, PMPRE, 
and PMPOST. MEANPRE refers to the arithmetic mean of 
AMPRE and PMPRE, while MEANPOST refers to the 
arithmetic mean of AMPOST and PMPOST. 
Patients were appointed to the research technician at 
monthly intervals. At these visits, peak flow readings were 
downloaded into a microcomputer. Pulmonary function 
tests were repeated, and subjects were re-instructed in the 
use of the peak flow meter if necessary. During the 
6-months of follow-up, patients were followed by their own 
physicians and treated in the customary manner. At no time 
did an investigator provide treatment or advice to the 
patient. This research protocol was approved by the insti- 
tutional committee on human research. All subjects gave 
informed consent. 
OTHER DEFINITIONS 
Respiratory decompensation was defined as an episode of 
dyspnea or wheezing which: 
1. was sufficiently severe to require emergency outpatient 
treatment or hospitalization; 
2. was attributed to increased airflow obstruction by the 
attending ED physician and 
3. was treated with nebulized bronchodilators and/or 
corticosteroids. 
Episodes treated only with antibiotics were excluded from 
analysis. 
A subject entered a period of stability (the baseline 
period) if all of the following conditions were met: 
1. the duration was at least 4 weeks; 
2. the period began at least 1 week after the start of PEFR 
monitoring; 
3. the period was separated from episodes of respiratory 
decompensation by at least 2 weeks; 
4. linear regression showed no temporal trends in PEFR 
and 
5. the mean PEFR was higher than any other plateau value 
in the observation period. 
Compliance was defined as the ratio of readings obtained 
to the number specified by the protocol, exclusive of those 
missed due to circumstances beyond the patient’s control. 
CALCULATED PARAMETERS 
FEV, and VC were converted to percent predicted accord- 
ing to the methods of Crapo (14). PEFR was converted 
to percent predicted by dividing observed by predicted 
values. Predicted PEFR was obtained from the following 
expression (15): 
log,(PEFR) = 
0.544 log,(age) - 0.015 1 (age) - 74,7/height + 5.48 
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where PEFR is expressed in 1 min - ‘, age in years, and 
height in centimeters. 
ANALYTICAL METHODS 
The derivation of linear models for PEFR consisted of 
three steps: (a) identifying the most common abnormality in 
the week prior to presentation for all cases; (b) plotting that 
variable against time to select a regression interval for each 
case; and (c) regressing AMPRE, AMPOST, PMPRE, 
PMPOST, MEANPRE and MEANPOST over the speci- 
fied interval. This approach was based upon the premise 
that the onset of respiratory decompensation should be 
related to changes in the most sensitive parameter and 
that the same regression interval should be used for all 
parameters in a given case. 
We conducted a preliminary analysis to identify the most 
common peak flow changes during respiratory decompen- 
sation. Nineteen episodes of respiratory decompensation 
occurred in subjects who had a period that qualified as a 
‘baseline’. For each parameter and for each patient, the 28 
baseline values were compared to values taken in the 4 days 
prior to each ED visit. The unpaired t-test was used because 
the latter readings were hypothesized to be an independent 
sample drawn from the population of baseline values 
characteristic of that particular patient. We found that 
AMPRE declined significantly in 42% of cases, AMPOST 
in 26%, PMPRE in 21%, PMPOST in 42%, MEANPRE in 
21%, and MEANPOST in 32%. 
Plots of AMPRE vs time were therefore examined for 
each episode in this study. The longest interval demon- 
strating a decline in AMPRE was chosen as the regression 
interval. Piecewise linear regression with unknown and 
specified breakpoints (16) was also used to identify inflec- 
tion points for intervals greater than 30 days. With this 
approach, temporal changes are represented by separate 
regression lines for different periods of time. The overall 
function can either be discontinuous, or the transition from 
one line to another can occur at a point common to both 
lines (‘the breakpoint’). 
Simple linear regression was used to model rates of 
change in AMPRE, AMPOST, PMPRE, PMPOST, 
MEANPRE, and MEANPOST prior to each ED visit. 
Least squares was used as the loss function. All continuous 
variables are expressed as mean & SD. P-values co.05 were 
considered significant. Statistical analysis was performed on 
a microcomputer equipped with a commercial software 
package (Systa@). 
Results 
Of the 28 male patients enrolled in this study, 12 experi- 
enced one or more episodes of respiratory decompensation. 
The mean age of the latter group was 67.0 & 8.7 years. 
Seventy-five percent were white, and 25% were of Hispanic 
origin. All subjects were current (n=l) or former (n=ll) 
smokers (mean number of pack-years = 85.8 & 55.6). The 
average age at the onset of respiratory symptoms was 
55.3 f 8.2 years. Physical activity was limited to 2.1 f 2.8 
TABLE 1. Baseline spirometry for 12 subjects with decom- 
pensated COPD 
Before After 
bronchodilators bronchodilators 
FEV, (1) 1.01 f 0.43 1.02 f 0.44 
FEV, (% predicted) 35.1 * 14.9% 35.5 f 15.0% 
vc (1) 2.78 f 1.06 2.83 f 1.10 
VC (% predicted) 62.7 + 22.9% 63.9 f 24.3% 
FEV,IVC ratio (%) 36.9 f 10.9% 36.7 + 9.5% 
PEFR (1 min - ‘) 182+76 193 f 61 
PEFR (% predicted) 32.7 f 14.4% 34.6 + 11.5% 
blocks of level ambulation and 0.3 * 0.4 flights of stairs. 
Seventy-five percent were on oxygen, while 33% were on 
maintenance prednisone. Spirometry confirmed that all 
subjects had an irreversible component of airflow obstruc- 
tion at entry (Table 1). The mean improvement after 
bronchodilators was 2.6 + 9.5%, and no subject improved 
by more than 14%. 
The 12 subjects had 22 episodes of respiratory decompen- 
sation during 1741 patient-days of observation. All epi- 
sodes were characterized by increased shortness of breath, 
15 by increased cough, and 10 by changes in sputum 
color or consistency. All cases were treated with nebulized 
bronchodilators, 19 were treated with intravenous or oral 
corticosteroids, and 16 were given antibiotics. 
Most patients found peak flow monitoring to be simple 
and convenient. Compliance was surprisingly high (86.0 * 
14.9%). However, two cases of respiratory decompensation 
in two subjects were excluded because they were non- 
compliant and recorded fewer than seven readings in the 
2 weeks prior to their ED visits. Ten of the remaining 20 
episodes were preceded by intervals of 30 days or more. 
Piecewise regression did not identify a breakpoint for any 
episode. However, inspection of the AMPRE vs time plots 
suggested an inflection point in seven cases and a continu- 
ous decline in the other 3 (Fig. 1). The other 10 cases of 
respiratory decompensation were preceded by intervals of 
less than 30 days. These intervals were bounded by the start 
of the study in five instances and by another ED visit in five. 
Linear regression was used to model changes in PEFR 
prior to each visit. Each regression was based upon the 
longest interval showing a decline in AMPRE. Subjects 
missed only 7.9% of the readings specified by the protocol 
during the intervals chosen for modelling. Ten episodes 
(50%) in seven subjects were characterized by a significant 
linear decline in at least one peak flow parameter (Table 2). 
The mean rates of change for the variables AMPRE, 
AMPOST, PMPRE, and PMPOST ranged from 0.22% to 
0.27% predicted per day (or 1.19 to 1.44 1 min - ’ day - ‘). 
Table 3 shows that the average decrement in these par- 
ameters varied from 30.0 to 33.8 1 min - ’ over regression 
intervals of 14-80 days. These declines represented 18.6- 
25.9% of their baseline values. Similar results were obtained 
for the daily averages (MEANPRE and MEANPOST). No 
ol ,,,,,,,,, j j ,,,,,,,,,,,,,,,,,,,,,,,,,,,,, (,,,,,,, 11 
94 106 153 
Days 
FIG. 1. Plot of AMPRE vs day for case 4A. Readings 
were not available between days 94 and 106. This subject 
presented to the emergency department with increased 
shortness of breath on day 153. Regression was per- 
formed between an apparent inflection point (first arrow) 
and the last recorded PEFR (second arrow). 
temporal trends were identified for 10 episodes experienced 
by the other five subjects. 
Discussion 
Respiratory decompensation is a significant cause of mor- 
bidity and mortality in chronic obstructive pulmonary 
disease. Many patients do not respond to initial treatment 
(17), and others relapse after demonstrating an initial 
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response (18). These poor outcomes suggest that early 
intervention is a more cost-effective strategy. However, this 
approach is feasible only if there are medications that can 
abort the disease process and if there is sufficient oppor- 
tunity for such medications to take effect. The window of 
opportunity, in turn, depends upon the amount of airway 
function lost and the rate at which this loss takes place. To 
our knowledge, no studies have been published that 
describe temporal changes in PEFR prior to ED visits for 
dyspnea. We conducted a prospective, double-blind study 
of peak flow monitoring in high-risk subjects to determine if 
a decline in PEFR antedates the need for emergency 
interventions. 
We found that AMPRE was the parameter most likely to 
be depressed during the week prior to exacerbation. Plots of 
AMPRE rs time were therefore used to identify appropriate 
regression intervals for each episode. For 10 episodes in 
seven patients, linear regression showed that the mean rate 
of loss for the four daily parameters varied from approxi- 
mately 1 to 1.5 1 min ’ day - I. This observation suggests 
that, in half of cases, respiratory decompensation is a 
gradual process occurring over weeks. 
In the remaining cases, no temporal trends were ident- 
ified for any PEFR parameter. One explanation is that peak 
flow monitoring was not sensitive enough to detect changes 
that were of clinical importance in these patients. This 
possibility is supported by the findings of others (19-21) 
that PEFR is less sensitive to changes than FEV,. Another 
possibility is that the rate of decline in PEFR was too fast 
in some cases to be detected by twice-daily monitoring. A 
third option is that respiratory decompensation was caused 
by factors other than airway dysfunction. Dyspnea can be 
caused by alterations in respiratory drive, alveolar disease, 
increased metabolic demands, hypoxia, hypercapnea, 
TABLE 2. Rates of change in PEFR (% predicted day ~ ‘) for 10 episodes of respiratory decompensation 
Episode no.? AMPRE AMPOST PMPRE PMPOST MEANPRE MEANPOST 
11B [80 days]$ - 0.09** - 0.09** - 0.06** - 0.05* - 0.07** - 0.07** 
10B [24 days] - 0.26** - 0.21** - 0.30** - 0.35** - 0.28** - 0.28** 
18A [67 days] - 0.11** - 0.12** - 0.09** - 0.10** - 0.10** -0.11** 
4A [40 days] - 0.11* - 0.15** - 0.01 - 0.14* - O-05 - 0.15** 
11A [27 days] - 0.58** - 0.17 - 0.49** - 0.12 - 0.56** - 0.17* 
31A [17 days] - 0.25 - 0.43* - 0.20 - 0.22 - 0.22 - 0.30* 
1C [40 days] - 0.10* - 0.02 0.04 0.04 - 0.02 0.002 
23B [18 days] -0.19 - 0.43* - 0.34 - 0.26 - 0.24 - 0.34 
1A [30 days] 0.05 - 0.05 - 0.30* - 0.19 - 0.13 - 0.15 
1B [I4 days] - 0.74 - 0.54 - 0.47 - 1.34* - 0.57 - 0.83 
Mean values 
% pred day ~ ’ - 0.24 - 0.22 - 0.22 - 0.27 - 0.22 - 0.24 
(95% CI) ( - 04- - 0.06) ( - 0.355 - 0.09) ( - 0.36 - 0.09) ( - 0.55-+O.Ol) ( - 0.377 - 0.08) ( - 04- - 0.07) 
1 mini’ day-’ - 1.29 - 1.19 - 1.19 - 1.44 - 1.21 - 1.28 
(95% CI) ( - 2.19- - 0.38) ( - 1.86- - 0.53) ( - 1.91- - 0.48) ( - 2,82- - 0.05) ( - 1.97- - 0.45) ( - 2.1 l- - 0.45) 
tThe number and letter refer to the patient and episode number, respectively. 
fThe number in brackets is the number of days used for modeling. 
*p<o.o5; **p<o.o1. 
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TABLE 3. Absolute change in PEFR (1 min - ‘) for 10 episodes of respiratory decompensation 
Episode no. AMPRE AMPOST PMPRE PMPOST MEANPRE MEANPOST 
11B [80 days] - 41.1 - 41.1 - 21.4 - 22.8 - 32.0 - 32.0 
10B [24 days] - 35.0 - 28.3 - 40.4 - 47.1 - 31.1 - 37.7 
18A [67 days] - 40.8 - 44.5 - 33.3 - 37.1 - 37.1 - 40.8 
4A [40 days] - 26.3 - 35.8 - 2.4 - 33.4 - 11.9 - 35.8 
11A [27 days] - 89.4 - 26.2 - 75.5 - 18.5 - 86.3 - 26.2 
31A [17 days] - 23.3 - 40.1 - 18.6 - 20.5 - 20.5 - 27.9 
1C [40 days] - 19.9 - 4.0 8.0 8.0 - 4.0 0.4 
23B [18 days] - 18.4 - 41.6 - 32.9 - 25.2 - 23.2 - 32.9 
1A [30 days] 7.5 - I.5 - 44.8 - 28.4 - 19.4 - 22.4 
1B [14 days] - 51.6 - 31.6 - 32.8 - 93.4 - 39.7 - 57.9 
Mean values 
Change (1 m ~ ‘)* - 33.8 - 30.7 - 30.0 - 31.8 - 31.2 - 31.3 
(95% CI) ( - 
5y;5-g1 
5.6) ( - 
4T9;o-420.4) 
( - 
4T5;o-81 
3.6) ( - 
5:;8-613.2) 
( - 47.4 - 15.0) ( - 4 1.9- - 20.7) 
% Baseline - 22.7 - 19.6 
(95% CI) (-42.1--9.7) (-29.0--11.8) (-33.1--8.6) (-29.1--8.2) (-36.3--9.0) (-27.2--12.0) 
*Over the specified regression interval. 
altered perceptions of respiratory workload, stimulation of 
peripheral reflexes, and psychological factors (22). Our 
study was not designed to evaluate these possibilities. 
To fit a linear model, it is preferable to identify an 
inflection in the series of readings that represents the start 
of each episode. In 13 cases, we could not identify the 
inception because the sampling intervals were too short. 
This problem arose because patients were recovering from 
previous episodes, hospitalized, or not yet enrolled in the 
study. Nevertheless, flow rates declined in a steady fashion 
from the point when monitoring began. The absence of a 
breakpoint should not have affected the regression slopes 
unless the early values were heavily leveraged. In seven 
cases, inspection of AMPRE vs time plots suggested an 
inflection. We attempted to confirm this observation by 
applying piecewise linear regression with unknown and 
specified breakpoints (16). Our failure to do so can be 
attributed to the considerable variation in PEFR measure- 
ments. Interrupted time series analysis was not performed 
because of the paucity of data points for most episodes. 
Although our patients had advanced airflow obstruction, 
compliance was very high. Over 90% of the readings 
specified by protocol were obtained for the time intervals 
used in this analysis. However, two subjects failed to obtain 
more than 50% of the required readings prior to their ED 
visits. Since this group was small, it is unclear if they 
differed from those whose exacerbations were studied. 
Nevertheless, we do not feel that the exclusion of these cases 
biased our observations because preliminary studies from 
our institution (Busby et al., unpublished) suggest that 
compliance is not correlated with the clinical features of 
COPD or the severity of airflow obstruction. 
Visual inspection of PEFR plots have been shown to be 
of great value in monitoring the clinical status of patients 
with COPD. Mitchell et al. (23) conducted a double-blind, 
randomized, placebo-controlled crossover study of pred- 
nisolone in 33 patients with chronic airflow limitation. 
Several methods were used to evaluate treatment response, 
including inspection of PEFR charts, 1Zmin walking dis- 
tance, FEV,, VC, oxygen cost, general well being, and 
breathlessness score. Visual inspection of the PEFR charts 
provided the best discrimination between prednisolone and 
placebo treatment. The authors concluded that visual 
inspect of PEFR readings is the most sensitive method for 
detecting a response to corticosteroids. 
The double-blind design of our study was critical because 
it eliminated expectation and incorporation biases (24). 
Expectation bias occurs when the patient becomes aware of 
his declining PEFR. He then seeks treatment because he is 
concerned about the readings, not about his symptoms. 
Incorporation bias occurs when the physician becomes 
aware of low readings. He is then more likely to encourage 
a patient to seek treatment and make the diagnosis of 
respiratory decompensation. In extreme cases, the readings 
are ‘incorporated’ into the body of evidence that supports 
the diagnosis. These biases would have exaggerated the 
association between declining PEFR and the clinical end- 
points of this study. Our use of a double-blind study design 
assures that the occurrence of low PEFR in respiratory 
decompensation is a meaningful one. 
In conclusion, respiratory decompensation is character- 
ized by a gradual decline in PEFR in about half of cases. 
Our findings suggest that there is a window of opportunity 
for early diagnosis and treatment of this problem. Further 
study should be done to elucidate the causes of respiratory 
distress in the other cases. 
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